Alpha 1-antitrypsin therapy mitigated ischemic stroke damage in rats

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Current acute ischemic stroke therapy relies on recombinant tissue plasminogen activator.
• Alpha-1 Antitrypsin (AAT) possesses anti-inflammatory, anti-apoptotic, and cytoprotective properties.
• AAT's potential therapeutic benefits in stroke warrant investigation.

Purpose of the Study:

• To evaluate the efficacy of AAT in improving outcomes following ischemic stroke.
• To test AAT's neuroprotective effects in a well-established rat stroke model.

Main Methods:

• Middle cerebral artery occlusion was induced in rats using endothelin-1.
• Rats received either intracranial or intravenous human AAT post-stroke.
• Sensorimotor function was assessed using cylinder and vibrissae tests.
• Infarct volumes were quantified using TTC assay or MRI.

Main Results:

• Human AAT treatment significantly reduced infarct volumes by 83% (local) and 63% (systemic) compared to controls.
• AAT administration led to significant improvements in sensorimotor deficits.
• P-values < .0001 and < .05 indicate statistical significance.

Conclusions:

• Human AAT demonstrates significant neuroprotective effects in a rat model of ischemic stroke.
• AAT effectively reduces infarct size and improves functional recovery.
• Further research is needed to explore AAT's mechanisms and efficacy in diverse models.